SCHEMBL12265301

SCHEMBL12265301

CN(C)CCCN1c2ccccc2Nc2ccccc21

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 9/20 0.66
CYP1A2 P05177 8/20 0.66
KMT2A Q03164 4/20 0.66
HTR1A P08908 7/20 0.63
SLC6A4 P31645 7/20 0.63
LMNA P02545 6/20 0.63
MAPT P10636 6/20 0.63
DRD2 P14416 6/20 0.63
HRH1 P35367 6/20 0.63
HTR2A P28223 5/20 0.63
HTR6 P50406 5/20 0.63
CHRM2 P08172 5/20 0.63
CHRM1 P11229 5/20 0.63
DRD1 P21728 5/20 0.63
SLC6A2 P23975 5/20 0.63
ADRA1A P35348 5/20 0.63
OPRM1 P35372 5/20 0.63
DRD3 P35462 5/20 0.63
MTOR P42345 5/20 0.63
KCNH2 Q12809 5/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Promazine SCHEMBL6855138 0.83 CYP2D6 (0.83) CYP2D6CYP1A2KMT2AHTR1ASLC6A4
SCHEMBL7164942 0.79 GAA (0.46) CYP2D6CYP1A2KMT2AMAPTDRD2
Dimetacrine SCHEMBL50120 0.79 CYP2D6 (1.00) CYP2D6CYP1A2KMT2AHTR1ASLC6A4
Dimetacrine SCHEMBL29578094 0.79 CYP2D6 (1.00) CYP2D6CYP1A2KMT2AHTR1ASLC6A4
Depramine SCHEMBL29489714 0.79 HTR1A (0.73) CYP2D6CYP1A2KMT2AHTR1ASLC6A4
Depramine SCHEMBL2108027 0.79 HTR1A (0.73) CYP2D6CYP1A2KMT2AHTR1ASLC6A4
SCHEMBL4571023 0.78 SMN1; SMN2 (0.40) CYP2D6CYP1A2KMT2AHTR1ASLC6A4
Imipramine SCHEMBL17004048 0.77 SLC6A4 (1.00) CYP2D6CYP1A2KMT2AHTR1ASLC6A4
Promazine SCHEMBL140489 0.77 CYP2D6 (1.00) CYP2D6CYP1A2KMT2AHTR1ASLC6A4
Promazine SCHEMBL9052694 0.77 CYP2D6 (1.00) CYP2D6CYP1A2KMT2AHTR1ASLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110223221-A1 STABILIZATION PROCESSES OF CATION RADICALS OF PHENOTHIAZINIC COMPOUNDS, COSMECEUTICAL FORMULATIONS AND METHODS FOR SKIN DISEASES AND DISTURBANCES PREVENTION NANTES ISELI LOURENCO 2011-09-15 US disclosed
US-20110223221-A1 STABILIZATION PROCESSES OF CATION RADICALS OF PHENOTHIAZINIC COMPOUNDS, COSMECEUTICAL FORMULATIONS AND METHODS FOR SKIN DISEASES AND DISTURBANCES PREVENTION NANTES ISELI LOURENCO 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110223221-A1 STABILIZATION PROCESSES OF CATION RADICALS OF PHENOTHIAZINIC COMPOUNDS, COSMECEUTICAL FORMULATIONS AND METHODS FOR SKIN DISEASES AND DISTURBANCES PREVENTION TYR, TXNRD2, NFE2L2 CYP2D6 569/4885CYP1A2 1198/4885KMT2A 1637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.